drugset
drugset / Trial / NCT00722202

Study Evaluating the Safety and Pharmacokinetics (PK) of Ascending Single IV Doses of ERB-257 in Healthy Japanese Males

NCT00722202 ↗

Phase 1 Completed 48 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of IV administered ERB-257 as single ascending doses to healthy Japanese male subjects

Timeline

Start
2008-10
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator ERB-257 Unknown 1 mg Intravenous
Comparator ERB-257 Unknown 4 mg Intravenous
Comparator ERB-257 Unknown 15 mg Intravenous
Comparator ERB-257 Unknown 45 mg Intravenous
Comparator ERB-257 Unknown 90 mg Intravenous
Comparator ERB-257 Unknown 180 mg Intravenous
Comparator ERB-257 Unknown 300 mg Intravenous

Indications

No indication recorded.